New Releases from NCBI BookshelfMaralixibat (Livmarli): CADTH Reimbursement Recommendation: Indication: For the treatment of cholestatic pruritus in patients with Alagille syndrome [Internet].​Maralixibat (Livmarli): CADTH Reimbursement Recommendation: Indication: For the treatment of cholestatic pruritus in patients with Alagille syndrome [Internet].

By /

CADTH recommends that Livmarli should be reimbursed by public drug plans for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) if certain conditions are met.

​ 

Leave a Comment

Your email address will not be published. Required fields are marked *

Useful Links

NEWREDMARS SKILL AND RESEARCH        FOUNDATION

Registration No: 771800548      Contact Number : +91-8249516996

©2021-2024. Newredmars Skill and Research Foundation. All Rights Reserved.

Scroll to Top